Abivax SA
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as … Read more
Abivax SA (ABVX) - Total Assets
Latest total assets as of September 2025: €652.05 Million EUR
Based on the latest financial reports, Abivax SA (ABVX) holds total assets worth €652.05 Million EUR as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Abivax SA - Total Assets Trend (2013–2024)
This chart illustrates how Abivax SA’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Abivax SA - Asset Composition Analysis
Current Asset Composition (December 2024)
Abivax SA's total assets of €652.05 Million consist of 83.2% current assets and 16.8% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €87.27 Million | 70.3% |
| Accounts Receivable | €15.66 Million | 7.6% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €2.67 Million | 1.3% |
| Intangible Assets | €6.61 Million | 3.2% |
| Goodwill | €18.42 Million | 9.0% |
Asset Composition Trend (2013–2024)
This chart illustrates how Abivax SA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Abivax SA's current assets represent 83.2% of total assets in 2024, an increase from 14.6% in 2013.
- Cash Position: Cash and equivalents constituted 70.3% of total assets in 2024, up from 7.6% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 11.0% of total assets, a decrease from 85.0% in 2013.
- Asset Diversification: The largest asset category is cash and equivalents at 70.3% of total assets.
Abivax SA Competitors by Total Assets
Key competitors of Abivax SA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Abivax SA - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Abivax SA generates 0.05x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Abivax SA is currently not profitable relative to its asset base.
Abivax SA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.86 | 3.04 | 1.51 |
| Quick Ratio | 7.86 | 3.00 | 1.51 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €540.53 Million | € 163.02 Million | € 12.72 Million |
Abivax SA - Advanced Valuation Insights
This section examines the relationship between Abivax SA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 16.43 |
| Latest Market Cap to Assets Ratio | 19.33 |
| Asset Growth Rate (YoY) | -37.3% |
| Total Assets | €205.23 Million |
| Market Capitalization | $3.97 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Abivax SA's assets at a significant premium ( 19.33x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Abivax SA's assets decreased by 37.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Abivax SA (2013–2024)
The table below shows the annual total assets of Abivax SA from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €205.23 Million | -37.25% |
| 2023-12-31 | €327.06 Million | +345.88% |
| 2022-12-31 | €73.35 Million | -33.54% |
| 2021-12-31 | €110.36 Million | +54.79% |
| 2020-12-31 | €71.30 Million | +37.83% |
| 2019-12-31 | €51.73 Million | -4.29% |
| 2018-12-31 | €54.05 Million | +0.43% |
| 2017-12-31 | €53.81 Million | -11.19% |
| 2016-12-31 | €60.60 Million | -20.55% |
| 2015-12-31 | €76.27 Million | +100.88% |
| 2014-12-31 | €37.97 Million | -1.29% |
| 2013-12-31 | €38.46 Million | -- |